title: Efficacy and safety of prostate vaporesection using a 120-W 2-μm continuous-wave Tm:YAG laser (RevoLix 2) in patients on continuous oral anticoagulant or antiplatelet therapy.
abstract: The aim of our current study was to demonstrate the efficacy and safety of vaporesection using a 120-W Tm:YAG laser (Revolix Duo) in patients with BPH receiving systemic anticoagulation or antiplatelet therapy. Between April 2010 and November 2011, a total of 76 patients using oral antiplatelet or anticoagulant (OA) agents affected by LUTS for BPH were underwent thulium vaporesection of the prostate (ThuVARP) using a 120-W 2-μm CW Tm:YAG laser and evaluated at 3- and 6-month follow-up. Of these, in 41 patients (group A) was performed vaporesection while receiving OA therapy. In 35 patients (group B), OA agents were discontinued 10 days before surgery. There were no significant differences in average vaporesection times, catheterization time, or hospital stay. There was no significant change in serum sodium level before and immediately after vaporesection in either group. Significant improvements compared to baseline were observed at each postoperative assessment in both groups for Qmax, PVR, IPSS, and QoL. More specifically, the IPSS score improved from 21.7 at baseline to 5.2 at 6 months in group A and from 20.7 to 4.5 in group B. At 6 months, Qmax increased 226 and 190 % for the 2 groups, respectively. The PVR decreased from 119 at baseline to 11 mL at 6 months in group A and from 125 to 11 mL in group B. ThuVARP is a safe and efficient procedure for patients with BPH, refractory to pharmacotherapy, who require active antiplatelet or anticoagulant therapy.
authors.affiliation: Department of Urology, University of Messina, Via Consolare valeria 1, 98126, Messina, Italy.
authors.forename: Luciano
authors.initials: L
authors.lastname: Macchione
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mucciardi
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gali'
authors.forename: Antonina
authors.initials: A
authors.lastname: Di Benedetto
authors.forename: Salvatore
authors.initials: S
authors.lastname: Butticè
authors.forename: Carlo
authors.initials: C
authors.lastname: Magno
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage*; D006417:Hematuria / Q000209:etiology; D006801:Humans; D053844:Lasers, Solid-State / Q000009:adverse effects / Q000627:therapeutic use*; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D061646:Operative Time; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000150:complications / Q000601:surgery*; D053448:Prostatism / Q000209:etiology / Q000601:surgery; D011788:Quality of Life; D012189:Retrospective Studies; D012720:Severity of Illness Index; D012964:Sodium / Q000097:blood; D014546:Urinary Catheterization
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D012964:Sodium
references.citation: Br J Urol. 1989 Dec;64(6):623-5
references.pmid: 2627636
references.citation: World J Urol. 2010 Feb;28(1):53-62
references.pmid: 20052586
references.citation: Arch Esp Urol. 2008 Nov;61(9):1037-43
references.pmid: 19140585
references.citation: J Urol. 2006 Apr;175(4):1428-32
references.pmid: 16516015
references.citation: BJU Int. 2006 Apr;97 Suppl 2:3-6; discussion 21-2
references.pmid: 16507045
references.citation: J Urol. 2002 Aug;168(2):610-3; discussion 614
references.pmid: 12131319
references.citation: J Endourol. 2008 Mar;22(3):539-43
references.pmid: 18355150
references.citation: Eur Urol. 2006 Nov;50(5):969-79; discussion 980
references.pmid: 16469429
references.citation: J Urol. 2011 Sep;186(3):977-81
references.pmid: 21791350
references.citation: BJU Int. 2011 Nov;108 Suppl 2:45-50
references.pmid: 22085127
references.citation: Eur Urol. 2009 Feb;55(2):368-75
references.pmid: 19022557
references.citation: Cochrane Database Syst Rev. 2004;(1):CD001987
references.pmid: 14973978
references.citation: BJU Int. 2010 Aug;106(3):368-72
references.pmid: 19912204
references.citation: BJU Int. 2006 Jan;97(1):85-9
references.pmid: 16336334
references.citation: Urology. 2010 Jan;75(1):194-9
references.pmid: 19819535
references.citation: Eur Urol. 2008 Feb;53(2):382-89
references.pmid: 17566639
references.citation: Eur Urol. 2007 Apr;51(4):1031-8; discussion 1038-41
references.pmid: 16945475
references.citation: Urology. 2002 Feb;59(2 Suppl 1):12-6
references.pmid: 11832309
references.citation: World J Urol. 2007 Jun;25(3):257-62
references.pmid: 17530258
references.citation: J Endourol. 2008 May;22(5):1041-5
references.pmid: 18377234
references.citation: World J Urol. 2014 Feb;32(1):165-72
references.pmid: 23657354
references.citation: World J Urol. 2011 Apr;29(2):211-6
references.pmid: 20577744
references.citation: World J Urol. 2010 Feb;28(1):45-51
references.pmid: 20063164